Skye Bioscience, Inc.

SKYE

Find Out if You Qualify for a Financial Reward by filling out the form below.

Skye Bioscience, Inc. Form












Stock Fraud Law Center does not share your information with others. There is no cost or obligation for you to submit.

Investigation Details

Skye issued a press release on June 10, 2024, “announc[ing] that its Phase 2a clinical trial of SBI-100 Ophthalmic Emulsion (“OE”) in patients with primary open-angle glaucoma “POAG”) or ocular hypertension (“OHT”) did not meet its primary endpoint for lowering intraocular pressure (“IOP”). Skye intends to discontinue clinical development and spending related to SBI-100 OE and any R&D associated with SBI-100, including its ophthalmology pipeline, and direct all clinical development resources to its metabolic program, extending its operating runway into 2027.”

Following this news, Skye’s stock price fell over 8% on June 10, 2024.

Active Cases

Ticker Symbol Company Name Join Deadline Join
APLT Applied Therapeutics, Inc. February 18, 2025 Join
BIOA BioAge Labs, Inc. March 10, 2025 Join
PCRX Pacira BioSciences, Inc. March 14, 2025 Join
NVO Novo Nordisk A/S March 25, 2025 Join
GO Grocery Outlet Holding Corp. March 31, 2025 Join
NEM Newmont Corporation April 01, 2025 Join
GSK GSK plc April 07, 2025 Join
NTLA Intellia Therapeutics, Inc. April 14, 2025 Join
MRK Merck & Co., Inc. April 14, 2025 Join